ReviewIn vivo (Athens, Greece)
Hyperglycemia in Critically Ill Patients: Current Approaches and Management Strategies.
Review in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperglycemia is frequently encountered in critically ill patients and is associated with adverse outcomes, including increased morbidity and mortality. It may be pre-existing due to diabetes mellitus or develop during hospitalization as stress hyperglycemia. This review aims to raise awareness among medical staff regarding the implications of hyperglycemia in critically ill patients, its pathophysiology, monitoring techniques, and current treatment protocols. Therefore, evidence from the international literature is analyzed, with specialized journals serving as reference points, focusing on the impact of glycemic variability, individualized patient management, and emerging technologies such as artificial intelligence-driven biosensors for glucose monitoring. Hyperglycemia is defined as a blood glucose level exceeding 7.0 mmol/l (125 mg/dl) before admission or surpassing 10.0 mmol/l (180 mg/dl) two hours postprandial. Monitoring can be conducted using arterial or capillary blood, continuous glucose monitoring systems, or artificial intelligence-enhanced biosensors. Regardless of their diabetic status, patients present unique clinical features. Those with pre-existing diabetes may experience hypoglycemia, diabetic ketoacidosis, hyperosmolar hyperglycemic state, electrolyte imbalances, and dehydration, necessitating meticulous monitoring and intervention. Special attention must be given to glycemic variability, maintaining levels between 3.8 and 10.0 mmol/l (70-180 mg/dl), and timely interventions to prevent complications. Current treatment protocols prioritize intravenous insulin infusion based on multiple clinical studies on hyperglycemic intensive care unit (ICU) patients. To minimize complications, maintaining glucose levels between 6.1 and 10.0 mmol/l (110-180 mg/dl) is recommended, balancing the risk of hypoglycemia. Hyperglycemia negatively impacts mortality due to systemic damage and the delayed detection of glucose dysregulation. This review underscores the necessity of personalized glycemic control strategies to improve patient outcomes in ICUs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.